Med24
metabolic-therapy 27. 10. 2026 • 2 min read • European journal of preventive cardiology (PubMed)

Redefining Cardiometabolic Disease: Expert Consensus on the CardioVascular-Kidney-Liver-Metabolic (CVKLM) Multiorgan Staging.

Cardiometabolic diseases increasingly manifest as interconnected dysfunction across the heart, vasculature, kidneys, liver, and metabolic system. The global rise in obesity, insulin resistance, and diabetes, together with therapies benefiting multiple organs, has reshaped the epidemiology and understanding of...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

Cardiometabolic diseases are increasingly recognized as interconnected dysfunction affecting the heart, vasculature, kidneys, liver, and metabolic system. The rise in obesity, insulin resistance, and diabetes has highlighted the need for a more comprehensive approach to understanding these conditions. A multidimensional staging system, the cardioVascular-kidney-liver-metabolic (CVKLM) framework, is presented. This framework independently grades involvement across these five organ systems, ranging from absent to advanced.

CVKLM Framework Overview

The CVKLM framework integrates established classifications including heart failure stages, vascular risk assessment, KDIGO chronic kidney disease stratification, metabolic dysfunction-associated steatotic liver disease (MASLD) criteria, contemporary definitions of diabetes, and clinical obesity. Unlike single-stage systems, CVKLM preserves organ-specific information and records coexisting abnormalities across domains.

Sponsored content

Framework Application

The framework is intended for clinical and research phenotyping and staging. It is designed to facilitate the systematic recognition of concomitant organ disease and to support existing diagnostic, referral, and treatment pathways. The prognostic significance and clinical utility of CVKLM profiles are yet to be determined. MASLD This framework offers a pragmatic approach to encompassing the full spectrum of cardiometabolic disease, from preclinical involvement to advanced multiorgan failure.

Original Scientific Source
European journal of preventive cardiology (PubMed)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.
metabolic-therapy

Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.

Insulin resistance is an important metabolic derangement contributing to the pathogenesis of type 2 diabetes, obesity, metabolic syndrome, and other chronic diseases, underlining the requirement for techniques that enable in vivo analysis of tissue-specific glucose metabolism. 18F-fluorodeoxyglucose positron emission...

10. 11. 2026 Read article →
Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.
metabolic-therapy

Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.

BACKGROUND: Although body mass index (BMI) is widely used to assess obesity-related health risks, it may fail to detect individuals with normal weight who present with significant cardiometabolic abnormalities. This phenotype, often overlooked in clinical practice, is associated with increased risk of cardiovascular...

30. 10. 2026 Read article →
Advertisement